EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSLDG00000002556
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSLDG00000024284
Gene Symbol: PIK3R5
4 Cross references
185 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSLDG00000004445
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSSLDG00000010221
Gene Symbol: LOC111660614
3 Cross references
232 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSSLDG00000013225
Gene Symbol: GART
3 Cross references
245 Possible Orthologues:

Plasma Kallikrein-Like

Ensembl ID : ENSSLDG00000007761
Gene Symbol: LOC111673270
2 Cross references
212 Possible Orthologues:

Plasminogen

Ensembl ID : ENSSLDG00000006762
Gene Symbol: PLG
3 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSLDG00000009240
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSLDG00000019685
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSSLDG00000003444
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSSLDG00000021837
Gene Symbol: LOC111671142
2 Cross references
174 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSSLDG00000016237
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).